Latest Healthcare News

Regis Healthcare is set to acquire Royal Freemasons Homes of Victoria’s home care business, adding around 480 clients and lifting its annual home care revenue to approximately $50 million. The deal, funded from existing cash, awaits regulatory approval and is expected to close in the second quarter of FY27.

Talius Group has secured a $1.65 million three-year deal to deploy its Talius One platform across three Queensland aged care facilities, boosting annual recurring revenue by $134,602 and deepening its relationship with Adventist Retirement Plus.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

Clever Culture Systems has doubled its large pharmaceutical customer base to eight, installed 34 APAS Independence instruments, and expects FY27 sales growth driven by existing and new customers. The company maintains a $1.7 million cash balance, raised $1.6 million in short-term debt, and is expanding validation services.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.